Results 111 to 120 of about 53,966 (229)

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 955-966, April 2026.
In the phase I/IIa GOING trial, an add‐on strategy with regorafenib followed by nivolumab showed a manageable safety profile and meaningful clinical activity in second‐line hepatocellular carcinoma, with a median overall survival of 25 months and 45% three‐year survival in sorafenib‐experienced patients.
Marco Sanduzzi‐Zamparelli, Ana Matilla, José Luis Lledo, Sergio Muñoz‐Martínez, María Varela, Mercedes Iñarrairaegui, Christie Perelló, Beatriz Mínguez, Neus Llarch, Laura Márquez, Antonio Guerrero, Gemma Iserte, Andrés Castaño‐García, Laura Carrión, Marta Fortuny, Jordi Rimola, Ángeles García‐Criado, Gema Domenech, Ferran Torres, José Rios‐Guillermo, Loreto Boix, Esther Samper, Àngels Kateb, Jordi Bruix, Maria Reig   +24 more
wiley   +1 more source

Correction: Improving the therapeutic efficacy of sorafenib for hepatocellular carcinoma by repurposing disulfiram. [PDF]

Front Oncol
Zhang G, Wang Y, Fuchs BC, Guo W, Drum DL, Erstad DJ, Shi B, DeLeo AB, Zheng H, Cai L, Zhang L, Tanabe KK, Wang X.   +12 more
europepmc   +1 more source

Improvements in Real‐World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment

European Journal of Haematology, Volume 116, Issue 4, Page 416-424, April 2026.
ABSTRACT Therapeutic options for newly diagnosed (ND) acute myeloid leukemia (AML) have increased in recent years, leading to a shift in the treatment paradigm from conventional, intensive chemotherapy toward targeted and less intensive therapy. Since 2017, there has been a surge in FDA approvals for novel therapies, including small molecule inhibitors
Thuy N. Ho, Patrick Willard, Graeme F. Murray, Li Liu, Nolan Wages, Hyun Lee, Keri R. Maher   +6 more
wiley   +1 more source

Transcriptomic Analysis Reveals an NRF2-Mediated Redox and Metabolic Reprogramming in Sorafenib-Resistant Hepatocellular Carcinoma Cells. [PDF]

BioTech (Basel)
Michilli A, Bassi C, Moshiri F, De Siena B, Marinaro R, Callegari E, Negrini M, Sabbioni S.   +7 more
europepmc   +1 more source

Efficacy and Safety of Donor Lymphocyte Infusion After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients

European Journal of Haematology, Volume 116, Issue 4, Page 443-449, April 2026.
ABSTRACT This retrospective study evaluates the efficacy and safety of donor lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT) in children. We describe the long‐term use of preemptive, prophylactic, and therapeutic DLI with a gradual dose increase in half‐log increments.
Dinah Walther, Jana Ernst, Carola Wollenhaupt, Susan Wittig, Manuela Härtel, Grit Brodt, Till Milde, Bernd Gruhn   +7 more
wiley   +1 more source

Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. [PDF]

Ther Adv Med Oncol
Qi H, Huang Y, Zhang W, Li J, Wang T, Ying Y, Chen B, Miao F, Li Q.   +8 more
europepmc   +1 more source

Lactate Metabolism‐Immune Regulation‐Related Gene Signature in Lower‐Grade Gliomas: Prognostic Model Development and Immune Characterization

The FASEB Journal, Volume 40, Issue 6, 31 March 2026.
Lactate metabolism‐immune regulation‐related gene signature (PLA2G2A, TNFRSF12A, VAV3) predicts glioma prognosis. PLA2G2A promotes ECM remodeling, tumor‐associated inflammation, and EMT, leading to enhanced proliferation, invasion, and unfavorable outcomes.
Enhao Zhang, Liangzhe Wei, He Ren, Jianfei Zhang, Hongqiao Yang, Meng Sun, Xiang Gao, Yi Huang   +7 more
wiley   +1 more source

Systematic review of the efficacy and safety of lenvatinib vs. sorafenib as first-line treatments for hepatocellular carcinoma. [PDF]

Clinics (Sao Paulo)
Bo W, Wang Z, Dong X, Zou J.
europepmc   +1 more source

Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT

International Journal of Cancer, Volume 158, Issue 6, Page 1690-1702, 15 March 2026.
What's new? The current standard of care for locally advanced or metastatic renal cell carcinoma (aRCC) is either a combination of two immune checkpoint inhibitors (CPI) or a CPI plus a tyrosine kinase inhibitor (TKI). Here, the authors simulate a head‐to‐head trial comparing the real‐world effectiveness of these combination therapies with TKI ...
Peter J. Goebell, Martin Bögemann, Arnd Nusch, Viktor Grünwald, Lothar Müller, Eyck von der Heyde, Uwe M. Martens, Carolin Lennartz, Michaela Koska, Karin Potthoff, Anja Kaiser‐Osterhues, Carsten Grüllich, Michael Staehler, Martina Jänicke, Dominik Marschner, the CARAT Registry Group   +15 more
wiley   +1 more source

Case Report: Sorafenib-induced rhabdomyolysis in a post-transplant patient with acute myeloid leukemia. [PDF]

Front Oncol
Ke L, Cao L, Li S, Zhou Z, Zheng P.
europepmc   +1 more source